

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer — Part 4 of a 4-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The recently presented five-year update of the Phase III PACIFIC trial of consolidation therapy with durvalumab for patients with unresectable Stage III non-small cell lung cancer (NSCLC) without disease progression after definitive platinum-based concurrent chemoradiation therapy demonstrated which of the following outcomes with durvalumab in the intention-to-treat population?**

 - Improvement in progression-free survival (PFS) only
 - Improvement in overall survival (OS) only
 - Improvement in both PFS and OS**
 - No improvement in either PFS or OS
- 2. Results of the IMpower010 study evaluating atezolizumab versus best supportive care after adjuvant chemotherapy demonstrated a significant benefit in disease-free survival with atezolizumab in which population of patients with resected Stage II to IIIA NSCLC?**

 - Patients with $\geq 1\%$ PD-L1 tumor expression**
 - Patients with EGFR mutations
 - Patients with ALK mutations
- 3. Which of the following chemotherapy and immunotherapy combination regimens was used in the KEYNOTE-189 study to demonstrate a survival benefit in comparison to platinum doublet chemotherapy for patients with metastatic nonsquamous NSCLC?**

 - Carboplatin/paclitaxel and atezolizumab
 - Carboplatin or cisplatin with pemetrexed and pembrolizumab**
 - Carboplatin/paclitaxel and pembrolizumab
- 4. Which of the following best describes the impact of adding neoadjuvant nivolumab to chemotherapy on surgical complications up to 90 days after definitive radiation in patients with NSCLC as observed in the CheckMate 816 trial?**

 - Any-grade surgery-related adverse events (AEs) were significantly higher with neoadjuvant nivolumab
 - Only Grade 3/4 surgery-related AEs were significantly higher with neoadjuvant nivolumab
 - Surgery-related AEs were not significantly increased with neoadjuvant nivolumab**
- 5. Which of the following immunotherapy agents is currently FDA-approved as single-agent first-line therapy for NSCLC?**

 - Pembrolizumab
 - Atezolizumab
 - Cemiplimab
 - A and B
 - A, B and C**